Our study showed that the benefits of anti-PD1 therapy in ICC were greater than those in other BTCs, while there was no significant differences in OS and PFS between the two groups with chemotherapy alone. The gene discussed is PDCD1; the disease is intrahepatic cholangiocarcinoma.